Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by ...
BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss. Shares fell about 2.5% in premarket trading to $20.99.
Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback